On September 3, 2025 Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, reported the acceptance of an abstract for poster presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Special Conference on Pancreatic Cancer Research taking place September 28-October 1 in Boston, Massachusetts (Press release, Cellectar Biosciences, SEP 3, 2025, View Source [SID1234655725]). The poster presentation will highlight preclinical data from CLR 121225, the Company’s novel actinium-based radio conjugate alpha-emitter for treatment in hypoxic pancreatic ductal adenocarcinoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to present our poster at the AACR (Free AACR Whitepaper) Special Conference on Pancreatic Cancer, further showcasing the potential of CLR 121225 for solid tumors," said Jarrod Longcor, chief operating officer of Cellectar. "We are encouraged that preclinical studies to date have demonstrated excellent activity, biodistribution and uptake of CLR 225 across multiple solid tumor animal models and are currently advancing IND-enabling activities."

Details of the poster presentation are as follows:

Title: "Targeting Lipid Rafts in Hypoxic Pancreatic Ductal Adenocarcinoma: Preclinical Evaluation of [225Ac]CLR 121225, a Novel Actinium-Based Radio-Conjugate"
Poster: B032
Date/Time: Tuesday, September 30, 6-9 p.m. Presenter: Jarrod Longcor